Hematological Malignancy
4
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 3 programs with unclassified modality
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Basilea PharmaceuticaSwitzerland - Allschwil
1 program1
isavuconazonium sulfate - intravenousPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MSDNemtabrutinib
Basilea Pharmaceuticaisavuconazonium sulfate - intravenous
Fate TherapeuticsGenetically engineered NK cells
Clinical Trials (3)
Total enrollment: 91 patients across 3 trials
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
Start: Aug 2023Est. completion: Nov 202340 patients
Phase 1Completed
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Start: Oct 2017Est. completion: Jul 201949 patients
Phase 1Completed
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Start: Oct 2019Est. completion: Apr 20202 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.